



Dr. Ricchiuti obtained his Ph.D. from the Department of Immunology and Molecular Biology at University Louis Pasteur in Strasbourg, France, and Sanofi Diagnostic Pasteur in Paris, France. He later trained in Laboratory Medicine at the University of Minnesota in Minneapolis, MN. From 1999-2011, Dr. Ricchiuti was the Laboratory Director of Specialty Immunoassays and Clinical Research Laboratories at Brigham and Women's Hospital, and Harvard Medical School (BWH/HMS), Boston, MA. From 2011 to 2015, he was Director of Immunology, Serology, Clinical Chemistry, and Toxicology at the University of Cincinnati Medical Center (UCMC, now UCHealth).

Dr. Ricchiuti joined Labcorp in Dublin, Ohio in 2015 as the Laboratory Director and a Discipline Director in immunology. He is also currently a Clinical Associate Professor at Ohio University, Department of Laboratory Medicine in Athens, Ohio. As a Discipline Director in immunology, Dr. Ricchiuti is continuously improving the ANA program at Labcorp by implementing automation and standardization in the immunofluorescence field. He has been instrumental in including the ICAP nomenclature of the patterns in patient reporting and is advancing Labcorp's expertise in the interpretation of ANA patterns.

At Labcorp Dr. Ricchiuti contributed to the validation and implementation of automated ANA testing using immunofluorescent Hep-2 cells, and new biomarkers that lead the way to improve patient care such as anti-CARP and anti-PAD4 which are both early markers of rheumatoid arthritis. He is very involved in the evaluation and implementation of new technologies.

Dr. Ricchiuti is actively involved in several professional associations: American Association of Clinical Chemistry (AACC), recently renamed Association for Diagnosis and Laboratory Medicine (ADLM), American Association of Bioanalysts (AAB) in which he is board certified, Association of Medical Laboratory Immunologists (AMLI), and American College of Rheumatology (ACR). During his tenure at BWH/HMS, he was the founder and chairman-elect of the AACC Translational Clinical Science Division and chairman-elect of the Northeast Chapter of the AACC in Boston, MA. He was also chairman-elect of the NIH Translational Research Core Labs Organization, Washington, DC. Currently, Dr. Ricchiuti is one of the founders and a committee member of the Disruptive Technology Award Competition (DATC) with ADML.